Novartis AG (CHIX:NOVNz)
CHF 87.96 -0.78 (-0.88%) Market Cap: 177.46 Bil Enterprise Value: 193.40 Bil PE Ratio: 11.84 PB Ratio: 4.80 GF Score: 56/100

Novartis AG Oncology Update Call Transcript

Jun 08, 2021 / 01:00PM GMT
Operator

Good morning and good afternoon, and welcome to the Novartis Oncology Update. (Operator Instructions) And the conference is being recorded. (Operator Instructions) A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. (Operator Instructions)

With that, I would like to hand over to Mr. Samir Shah, Head of Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you and good morning and good afternoon, everybody. Thank you so much for taking the time to join us today. We appreciate it's a really busy time especially today with the various investor-related calls. It's my pleasure to have with us today, as we go through the key highlights from ASCO, Susanne Schaffert, who's the President of Novartis Oncology; Alice Shaw, Global Head of Translational Clinical Oncology at the Novartis Institute of Biomedical Research; Sidonie Daffner, who's the President of Radioligand Therapies; and Jeff Legos, the Global Head of Oncology Development within Novartis

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot